Student’s Name: Nabor, Melagrose Year Level & Section 2-A Date: 10-15-2021

Pharmacological Nursing Study (Drug Study) Worksheet

Generic/Bran Dose Strength &

d Name & Formulation Adverse/Side Effects & Drug Nursing Responsibilities Rationale Client Teaching Evaluation
Indication/ Mechanism of Drug Action Interaction
Drug
Classification
Male Indication Adverse Effects:
 Anemias, certain cancers, and  In prepubertal  Assess for the mentioned  Administer with food  Allergy to androgens  Monitor patient
oxandrolone/Oxa T1/2: 9 h angioedema males: virilization (e.g. phallic cautions and if GI effects are or other ingredients response to therapy (e.g.
ndrin/Anabolic Metabolism: liver  Promote weight gain and tissue repair enlargement, hirsutism, contraindications (e.g. severe to relieve GI in the drug. Prevent increase in haematocrit,
Steroids Excretion: kidney in debilitated patients and protein increased skin pigmentation). drug allergy, CV diseases, distress. hypersensitivity protein anabolism, etc.).
(urine) anabolism in patients who are receiving  In postpubertal etc.) to prevent any  Monitor endocrine reactions.  Monitor for adverse
long-term corticosteroid therapy. males: inhibition of testicular untoward complications. and hepatic  Liver effects (e.g. androgenic
 Also known to be used illegally for the function, gynecomastia,  Perform a thorough functions, serum dysfunction. Drug is effects, serum
enhancement of athletic performance testicular atrophy, priapism physical assessment (e.g. electrolytes before metabolized in the electrolyte disturbances,
by promoting increased muscle mass, (painful and continual skin assessment, mental and periodically liver and are known epiphyseal closure,
hematocrit, strength, and endurance. erection of the penis), status, abdominal during therapy so to cause hepatic hepatic dysfunction,
baldness, and change in examination, etc.) to that dose can be toxicity. etc).
libido. establish baseline data adjusted  Coronary  Evaluate patient
Interacton: before drug therapy appropriately and disease. Potentional understanding on drug
 Potential interaction with begins, to determine severe adverse effects increase in cholesterol therapy by asking
oral anticoagulants effectiveness of therapy, can be avoided level through the patient to name the
 Potentially decreased need and to evaluate for effect of the drug on drug, its indication, and
for antidiabetic agents occurrence of any adverse the liver. adverse effects to watch
effects associated with  for.
 Altered lipid metabolism and drug therapy.
Prostate/breast cancer
lack of effectiveness for lipid- in males. Exacerbated  Monitor patient
lowering agents by the effects of these compliance to drug
drugs. therapy.
female
raloxifene/ Evista/ T1/2: Not known Indication Adverse Effects:
Estrogen Metabolism: liver  Women receiving any of these drugs  Assess for the mentioned  Administer drug with  Allergy to estrogen  Monitor patient
should receive an annual medical cautions and food to prevent GI
Receptor Excretion: urine  Raloxifene has been contraindications (e.g. upset.
receptor response to therapy
Modulators examination, including breast associated with GI upset, modulators. Prevent (palliation of signs and
examination and Pap smear, to nausea, and vomiting.
drug allergies,  Provide analgesic for hypersensitivity symptoms of
monitor for adverse effects and cardiovascular diseases, relief of headache as reactions. menopause, prevention
underlying medical conditions.  Changes in fluid balance to prevent any untoward appropriate.
may cause headache, complications.  Pregnancy, of pregnancy, decreased
 Not indicated during pregnancy or dizziness, visual changes,  Provide small, lactation. Potential risk factors for coronary
lactation because of potential for  Perform a thorough frequent meals to effects on the fetus or artery disease, and
and mental changes. physical assessment (e.g.
adverse effects on the fetus or neonate. assist with nausea and neonate. palliation of certain
 Specific estrogen receptor bowel sounds, skin vomiting. cancers).
stimulation may cause hot assessment, vital signs, to  History of
flashes, skin rash, edema,  Monitor for swelling venous thrombosis or  Monitor for adverse
establish baseline data and changes in vision effects (e.g. GI upset,
and vaginal bleeding. before drug therapy smoking. Increased
Interation or fit of contact lenses risk of blood clot edema, changes in
begins, to determine to monitor for fluid secondary sex
formation if smoking
 Cholestyramine: effectiveness of therapy, retention and fluid and estrogen are characteristics,
reduced raloxifene and to evaluate for changes. combined. headaches,
absorption occurrence of any adverse  Provide comfort thromboembolic
 Highly protein-bound effects associated with measures to help episodes, and
drugs (e.g. drug therapy. patient tolerate drug breakthrough bleeding).
diazepam, ibuprofen,  Assist with pelvic and effects.  Evaluate patient
indomethacin, breast examinations.  Provide safety understanding on drug
naproxen): interference  Arrange for ophthalmic measures (e.g. therapy by asking
on binding sites examination especially for adequate lighting, patient to name the
 Warfarin: decreased patients who are wearing raised side rails, etc.) drug, its indication, and
prothrombin time if contact lenses because to prevent injuries. adverse effects to watch
taken with raloxifene hormonal changes can  Educate client on for.
alter the fluid in drug therapy to  Monitor patient
the eye and curvature of promote compliance to drug
the cornea, which can understanding and therapy.
change the fit of contact compliance.
lenses and alter visual
acuity.
 Monitor laboratory test
results (e.g. urinalysis,
renal and hepatic
function tests, etc.) to
determine possible need
for a reduction in dose
and evaluate for toxicity.